Effects of coenzyme Q10 supplementation (300 mg/day) on antioxidation and anti-inflammation in coronary artery disease patients during statins therapy: a randomized, placebo-controlled trial by unknown
Lee et al. Nutrition Journal 2013, 12:142
http://www.nutritionj.com/content/12/1/142RESEARCH Open AccessEffects of coenzyme Q10 supplementation
(300 mg/day) on antioxidation and
anti-inflammation in coronary artery disease
patients during statins therapy: a randomized,
placebo-controlled trial
Bor-Jen Lee1, Yu-Fen Tseng2, Chi-Hua Yen3,4,5 and Ping-Ting Lin2,6*Abstract
Background: High oxidative stress and chronic inflammation can contribute to the pathogenesis of coronary artery
disease (CAD). Coenzyme Q10 is an endogenous lipid-soluble antioxidant. Statins therapy can reduce the biosynthesis
of coenzyme Q10. The purpose of this study was to investigate the effects of a coenzyme Q10 supplement (300 mg/d;
150 mg/b.i.d) on antioxidation and anti-inflammation in patients who have CAD during statins therapy.
Methods: Patients who were identified by cardiac catheterization as having at least 50% stenosis of one major
coronary artery and who were treated with statins for at least one month were enrolled in this study. The subjects
(n = 51) were randomly assigned to the placebo (n = 24) and coenzyme Q10 groups (Q10-300 group, n = 27). The
intervention was administered for 12 weeks. The concentrations of coenzyme Q10, vitamin E, antioxidant enzymes
activities (superoxide dismutase, catalase, and glutathione peroxidase), and inflammatory markers [C-reactive protein
(CRP), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6)] were measured in the 42 subjects (placebo, n = 19;
Q10-300, n = 23) who completed the study.
Results: The levels of the plasma coenzyme Q10 (P < 0.001) and antioxidant enzymes activities (P < 0.05) were
significantly higher after coenzyme Q10 supplementation. The levels of inflammatory markers (TNF-α, P = 0.039) were
significantly lower after coenzyme Q10 supplementation. The subjects in the Q10-300 group had significantly higher
vitamin E (P = 0.043) and the antioxidant enzymes activities (P < 0.05) than the placebo group at week 12. The level of
plasma coenzyme Q10 was significantly positively correlated with vitamin E (P = 0.008) and antioxidant enzymes
activities (P < 0.05) and was negatively correlated with TNF-α (P = 0.034) and IL-6 (P = 0.027) after coenzyme Q10
supplementation.
Conclusion: Coenzyme Q10 supplementation at 300 mg/d significantly enhances antioxidant enzymes activities and
lowers inflammation in patients who have CAD during statins therapy.
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Cardiovascular disease is the leading cause of death
worldwide [1]. Hyperlipidemia is a major risk factor for
coronary artery disease (CAD). A higher level of low
density lipoprotein-cholesterol (LDL-C) can increase the
incidence of CAD [2]. The 3-hydroxy-3-methylglutaryl
coenzyme A reductase (HMG-Co A reductase) inhibi-
tors (statins) have been the most popular drugs for redu-
cing the level of LDL-C, and they are an established
strategy for decreasing the frequency of CAD events [3].
Coenzyme Q10 (also called ubiquinone) is a lipid-soluble
benzoquinone that has 10 isoprenyl units in its side chain
and is a key component of the mitochondrial respiratory
chain for adenosine triphosphate synthesis [4,5]. Statins
can decrease the synthesis of cholesterol and other mole-
cules downstream of mevalonate. Mevalonate is a precur-
sor of coenzyme Q10. Statins not only lower the blood
cholesterol but also lower the level of coenzyme Q10 [6-9].
Higher levels of oxidative stress and inflammation play
a role in the development of CAD [10,11]. Coenzyme Q10
is an intracellular antioxidant that protects the membrane
phospholipids, mitochondrial membrane protein, and LDL-
C from free radical-induced oxidative damage [12,13]. Re-
cently, we have demonstrated that coenzyme Q10 had a
cardio-protective impact on CAD. A higher level of plasma
coenzyme Q10 (≥ 0.52 μmol/L) was significantly associated
with a reduced the risk of CAD [14]. We proposed that a
higher dose of coenzyme Q10 (> 150 mg/d) might show
better antioxidation in patients who have CAD [15].
The circulating levels of C-reactive protein (CRP), tumor
necrosis factor-α (TNF-α), and interleukin-6 (IL-6) are
positively correlated with the risk of primary and recurrent
myocardial infarction and death [16-18]. Adiponectin is an
anti-inflammatory marker that is potentially antiathero-
genic and is secreted in abundance by adipocytes [19]. Its
level might be related to the development of CAD [20]. In
a recent study [21], we reported that coenzyme Q10 admin-
istered at 150 mg/d decreased the inflammatory marker -
IL-6 but had no effect on CRP in patients with CAD. Thus,
we hypothesize that a higher dose of coenzyme Q10 (>
150 mg/d) would provide better anti-inflammation in CAD
patients. The purpose of this study was to investigate the
effect of coenzyme Q10 supplementation (300 mg/day,
150 mg/b.i.d) on antioxidant enzymes activities and anti-
inflammation in patients with CAD during statins therapy.
Methods
Participants
This study was designed as a single blinded, randomized,
parallel, placebo-controlled study. CAD patients were re-
cruited from the cardiology clinic of Taichung Veterans
General Hospital, which is a teaching hospital in central
Taiwan. CAD was identified by cardiac catheterization as
having at least 50% stenosis of one major coronary arteryor receiving percutaneous transluminal coronary angio-
plasty (PTCA). The subjects in this study were treated
with statins therapy for at least 1 month. The subjects
with diabetes, liver, or renal diseases, or who currently
use vitamin supplements were excluded. Informed con-
sent was obtained from each subject. This study was ap-
proved by the Institutional Review Board of Taichung
Veterans General Hospital, Taiwan.
With a sample size calculation, we expected that the
change in the levels of antioxidant enzymes activities
would be 5.0 ± 7.0 U/mg of protein after coenzyme Q10
supplementation; therefore, the desired power was set at
0.8 to detect a true fact and at an α value equal to 0.05
with a minimal sample of 18 in each intervention group.
We enrolled 51 CAD patients in this study and used
random numbers table to random assign the subjects to
the placebo (n = 24) or to the coenzyme Q10 [300 mg/day
(Q10-300 group), n = 27] groups. The female subjects
in this study were postmenopausal women who were not
receiving hormone therapy. The coenzyme Q10 and pla-
cebo (starch) capsules were commercially available prepa-
rations (New Health Taiwan Co., Ltd.). The intervention
was administered for 12 weeks. The subjects were
instructed to take two capsules daily (coenzyme Q10 sup-
plements 300 mg/d, 150 mg/b.i.d). To monitor compliance,
the researchers reminded subjects to check the capsules
bag every 4 weeks to confirm that the bag was empty. The
researcher also asked some questions to the subjects, such
as ①When did you take the supplements? (We advised
subjects to take the supplements after a meal); ②How
many times did you take the supplements every day? (We
advised subjects to take the supplements two times per
day); ③How many capsules did you take of the supple-
ments each time? (We advised the subjects to take one
capsule of supplement each time); and ④How did you feel
after taking the supplements? (for monitoring adverse ef-
fects), and then we checked the capsule bags. We placed
56 capsules in each bag, and the bag should be emptied
after 4 weeks of taking the supplements. If the subjects
took the empty bag back and answered the questions cor-
rectly, the researcher then gave them another bag of cap-
sules. In addition, we also measured the concentration of
coenzyme Q10 every 4 weeks supplementation for monitor
the compliance of the subjects. The age, blood pressures,
and smoking, drinking, and exercise habits of all of the
subjects were recorded. The body weight and height were
measured; the body mass index (BMI) was then calculated.
Blood collection and biochemical measurements
Fasting venous blood samples (15 mL) were obtained to
estimate the hematological and vitamin status. Blood
specimens were collected in Vacutainer tubes (Becton
Dickinson, Rutherford, NJ, USA) that contained EDTA
as an anticoagulant or that contained no anticoagulant
CAD subjects who were treated with 
statins for at least 1 month (n = 51)
Placebo (n = 24)
12 weeks
Randomized
Q10-300 (n = 27)
Lost to follow up (n = 5) Lost to follow up (n = 4)
Completed (n = 19) Completed (n = 23)
Figure 1 Flow diagram. Q10-300, coenzyme Q10 300 mg/d.
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fugation (3,000 rpm, 4°C, 15 minutes) and were then stored
at -80°C until analysis. Hematological entities [serum cre-
atinine, total cholesterol (TC), triglyceride, LDL-C, and high
density lipoprotein-cholesterol (HDL-C)] were measured
by an automated biochemical analyzer (Hitachi-7180E,
Tokyo, Japan). The level of CRP was quantified by particle-
enhanced immunonephelometry with an Image analyzer
(Dade Behring, IL, USA). Plasma TNF-α (R&D Systems
Inc., Minneapolis, USA), IL-6 (eBioscience, CA, USA), and
adiponectin (BioVendor, Brno, Czech Republic) levels were
measured by enzyme-linked immunosorbent assay (ELISA)
using commercially available kits and according to the in-
structions made available from the suppliers.
Plasma coenzyme Q10 and vitamin E were measured
by high-performance liquid chromatography (HPLC) and
were detected by a UV detector at 275 nm and 292 nm, re-
spectively [22,23]. The red blood cell (RBC) samples were
washed with normal saline after removing the plasma.
Then, the RBC were diluted with 25x sodium phosphate
buffer for superoxide dismutase (SOD) and glutathione
peroxidase (GPx) measurements, and with 250x sodium
phosphate buffer for catalase (CAT) measurement. The
antioxidant enzymes activities (CAT, SOD, and GPx) were
determined in the fresh samples and the methods for
measuring these activities have been described previously
[24-26]. The protein content of the plasma and RBC was
determined based on the biuret reaction of the BCA kit
(Thermo, Rockford, IL, USA). The values of the antioxi-
dant enzymes activities were expressed as unit/mg of pro-
tein. All of the analyses were performed in duplicate.
Statistical analyses
The data were analyzed using SigmaPlot software (ver-
sion 12.0, Systat, San Jose, CA, USA). The normality of
the distribution of the variables was evaluated using the
Shapiro-Wilk test, and the normally distributed variables
were age, waist circumference, the ratio of waist to hip,
BMI, TC, LDL-C, HDL-C, the frequency of smoking and
exercise, the ratio of vitamin E to TC, SOD, and IL-6.
The multiple linear regression analyses were performed to
examine the time and the interventional effects on the
variables (coenzyme Q10, vitamin E, antioxidant enzymes,
and inflammation markers as a dependent variable). We
set the dummy variables for the time (0 = baseline, 1 =
week 12) and the intervention (0 = placebo, 1 = coenzyme
Q10 supplementation). If the variables had significantly ef-
fects by the time or the intervention, then the intergroup
differences (intervention effect) between the placebo and
the Q10-300 groups were evaluated by the Student’s t-test
or the Mann-Whitney rank sum test; within a group (time
effect), the paired t-test or the Wilcoxon signed rank tests
were used. When comparing the changed levels of coen-
zyme Q10, vitamin E, antioxidant enzymes activities andinflammatory markers between the placebo and the Q10-
300 groups, the Student’s t-test or the Mann-Whitney
rank sum test was used. For categorical response variables,
the differences between two groups were assessed by the
Chi-square test (parametric method) or the Fisher’s exact
test (non-parametric method). To examine the relation-
ships of coenzyme Q10 concentration with the level of
vitamin E, antioxidant enzymes activities, and inflamma-
tory markers after the supplementation, the Pearson prod-
uct moment correlations were used in the parametric data
and the Spearman rank order correlations were used in
the non-parametric data. The results were considered to
be statistically significant at p < 0.05. The values presented
in the text are means ± standard deviation (SD).Results
Study participant characteristics
The sampling and trial profiles are summarized in Figure 1,
along with the number of subjects who completed the
study in each group. Table 1 shows the demographic data
and the health characteristics of the subjects. There were
no significant differences between the two groups with re-
spect to age, BMI, blood pressure, anthropometric mea-
surements, hematological entities (serum creatinine and
lipid profiles), and the frequency of smoking, drinking, or
exercise at baseline.
Table 1 Characteristics of subjects
Placebo (n = 19) Q10-300 (n = 23) P values1
Male / female (n) 12 / 7 19 / 4 0.180a
Age (y) 66.5 ± 11.1 (68.0) 71.7 ± 11.5 (72.0) 0.148b
SBP (mmHg) 133.6 ± 6.9 (130.0) 131.8 ± 12.0 (130.0) 0.175c
DBP (mmHg) 75.5 ± 5.2 (74.0) 73.8 ± 7.1 (70.0) 0.234c
Waist circumference (cm) 95.2 ± 10.0 (96.0) 92.1 ± 11.3 (90.0) 0.362b
Waist hip ratio 1.0 ± 0.1 (0.9) 0.9 ± 0.1 (0.9) 0.743b
BMI (kg/m2) 26.7 ± 3.2 (26.5) 25.9 ± 3.5 (25.3) 0.438b
Current smoker2, n (%) 4 (21.1%) 1 (4.3%) 0.158d
Drink alcohol3, n (%) 2 (10.5%) 3 (13.0%) 1.000a
Exercise4, n (%) 13 (68.4%) 15 (65.2%) 0.913d
Creatinine (μmol/L) 123.8 ± 70.7 (106.1) 114.9 ± 44.2 (97.2) 0.780c
TC (mmol/L) 4.5 ± 1.3 (4.4) 5.0 ± 1.0 (4.9) 0.175b
TG (mmol/L) 1.7 ± 1.3 (1.3) 1.6 ± 0.9 (1.4) 0.791c
LDL-C (mmol/L) 2.7 ± 0.8 (2.5) 3.0 ± 0.8 (3.1) 0.165b
HDL-C (mmol/L) 1.4 ± 0.4 (1.4) 1.4 ± 0.3 (1.4) 0.984b
Data are mean ± SD (median).
1values are significantly different between the placebo and Q10-300 groups.
2current smoker: individual currently smoking one or more cigarettes per day.
3drink alcohol: individual drinking one or more drink per day regularly.
4exercise: individual exercise at least 3 times every week.
adata were analyzed by the Fisher’s exact test.
bdata were analyzed by the Student’s t-test.
cdata were analyzed by the Mann-Whitney rank sum test.
ddata were analyzed by the Chi-square test.
BMI, body mass index; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low density lipoprotein-cholesterol; SBP, systolic blood
pressure; TC, total cholesterol; TG, triglyceride.
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The effects of coenzyme Q10 supplementation on the levels
of coenzyme Q10 and vitamin E are shown in Figure 2.
The plasma coenzyme Q10 concentration (P < 0.001) and
the ratio of coenzyme Q10 to TC (P < 0.001) were signifi-
cantly increased after coenzyme Q10 supplementation. The
subjects in the Q10-300 group had significantly higher
levels of coenzyme Q10 (P < 0.001), ratio of coenzyme Q10
to TC (P < 0.001), and vitamin E (P = 0.043), and ratio of
vitamin E to TC (P = 0.025) than those in the placebo group
at week 12.
Antioxidant enzymes activities
The effects of coenzyme Q10 supplementation on the
antioxidant enzymes activities are shown in Figure 3.
The activities of SOD (P = 0.001), CAT (P = 0.009), and
GPx (P = 0.021) were significantly increased after coen-
zyme Q10 supplementation. The subjects in the Q10-
300 group had significantly higher activities of SOD (P =
0.005), CAT (P = 0.025), and GPx (P = 0.040) than those
in the placebo group at week 12.
Inflammatory markers
The effects of coenzyme Q10 supplementation on the
levels of inflammatory markers are shown in Figure 4. Thesubjects in the Q10-300 group had a significantly lower
level of TNF-α than those in the placebo group at week 12
(P = 0.039). There were no effects on the level of CRP, IL-
6, and adiponectin after 12 weeks of supplementation.
Changed levels of coenzyme Q10, vitamin E, antioxidant
enzymes activities, and inflammatory markers after
supplementation
The changed levels of coenzyme Q10, vitamin E, antioxi-
dant enzymes activities, and inflammatory markers after
the supplementation are shown in Table 2. The Changed
levels of coenzyme Q10 (P < 0.001), the ratios of coenzyme
Q10 to TC (P < 0.001), vitamin E (P = 0.046), the ratios of
vitamin E to TC (P = 0.032), antioxidant enzymes activities
(SOD, P = 0.034; CAT, P = 0.033; GPx, P = 0.042), and in-
flammatory markers (TNF-α, P = 0.036; IL-6, P = 0.040)
were significantly different between the placebo and the
Q10-300 groups.
Correlations between coenzyme Q10, vitamin E,
antioxidant enzymes activities, and inflammatory markers
The correlations between coenzyme Q10, vitamin E, anti-
oxidant enzymes activities, and inflammatory markers
after coenzyme Q10 supplementation are shown in Table 3.





Figure 2 Coenzyme Q10 and vitamin E concentrations. Data are means ± SD. □ week 0, ■ week 12. *Values were significantly different after
intervention within the group (***P < 0.001). †Values were significantly different between the placebo and Q10-300 groups (†P < 0.05, †††P < 0.001).
TC, total cholesterol.
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dant enzymes activities (SOD, r = 0.38, P = 0.011; CAT, r =
0.30, P = 0.0038; GPx, r = 0.32, P = 0.043), and the inflam-
matory markers (TNF-α, r = -0.33, P = 0.034; IL-6, r = -0.38,
































Figure 3 Antioxidant enzymes activities. Data are means ± SD. □ week
within the group (*P < 0.05, **P < 0.01). †Values were significantly different b
catalase; GPx, glutathione peroxidase; SOD, superoxide dismutase.Discussion
In this clinical trial, we have demonstrated that coen-
zyme Q10 at the dose of 300 mg/d for 12 weeks in-
creases the antioxidant enzymes activities (SOD, CAT,
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Figure 4 The level of inflammatory markers. Data are means ± SD. □ week 0, ■ week 12. †Values were significantly different between the
placebo and Q10-300 groups (†P < 0.05). CRP, C-reactive protein; IL-6, interleukin-6; TNF-α, tumor necrosis factor-α.
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tered coenzyme Q10 (300 mg/d) to patients with ische-
mic heart disease for 1 month, and they observed that
those patients’ extracellular superoxide dismutase activity
and endothelium-dependent vasodilatation were improvedTable 2 Changed levels of coenzyme Q10, vitamin E, antioxid
after supplementation
Placebo (n = 19)
Coenzyme Q10 (μmol/L) −0.01 ± 0.09 (-0.03)
Coenzyme Q10/TC (μmol/mmol) −0.01 ± 0.07 (-0.00)
Vitamin E (μmol/L) −3.35 ± 4.51 (-3.08)
Vitamin E/TC (μmol/mmol) −0.88 ± 1.45 (-0.55)
SOD (U/mg protein) 1.63 ± 21.54 (3.63)
CAT (U/mg protein) −1.42 ± 8.26 (-1.18)
GPx (U/mg protein) 0.91 ± 3.70 (-0.24)
CRP (mg/L) 0.39 ± 1.24 (0.00)
TNF-α (pg/mL) 0.17 ± 0.77 (0.08)
IL-6 (pg/mL) 0.08 ± 0.64 (-0.11)
Adiponectin (μg/mL) 0.36 ± 2.89 (0.30)
Data are mean ± SD (median).
1values are significantly different between the placebo and the Q10-300 groups.
adata were analyzed by the Student’s t-test.
bdata were analyzed by the Mann-Whitney rank sum test.
CAT, catalase; CRP, C-reactive protein; GPx, glutathione peroxidase; IL-6, interleukin-6; Safter supplementation. Antioxidant enzymes such as SOD,
CAT, and GPx are the first line of defense against reactive
oxygen species [28], and a decrease in their activities con-
tributes to the elevated oxidative stress in CAD patients
[14]. Our previous results showed that coenzyme Q10 at aant enzymes activities, and inflammatory markers
Q10-300 (n = 23) P values1
1.10 ± 0.54 (1.26) < 0.001b
0.25 ± 0.11 (0.25) < 0.001b
−0.29 ± 4.03 (-0.83) 0.046b
0.07 ± 1.08 (0.11) 0.032a
15.90 ± 20.48 (12.91) 0.034a
6.17 ± 11.28 (3.18) 0.033b
4.62 ± 6.52 (2.15) 0.042b
−0.20 ± 0.73 (0.00) 0.343b
−0.30 ± 0.35 (-0.26) 0.036b
−0.52 ± 0.79 (-0.14) 0.040a
0.19 ± 1.88 (-0.20) 0.71b
OD, superoxide dismutase; TC, total cholesterol; TNF-α, tumor necrosis factor-α.
Table 3 Correlations between coenzyme Q10, vitamin E,
antioxidant enzymes activities, and inflammatory
markers after coenzyme Q10 supplementation
Coenzyme Q10 (μmol/L) r1 (P values)
Vitamin E (μmol/L) 0.41 (0.008)a
SOD (unit/mg protein) 0.38 (0.011)a
CAT (unit/mg protein) 0.30 (0.038)b
GPx (unit/mg protein) 0.32 (0.043)b
CRP (mg/L) −0.08 (0.621)b
TNF-α (pg/mL) −0.33 (0.034)b
IL-6 (pg/mL) −0.38 (0.027)a
Adiponectin (μg/mL) −0.21 (0.190)b
1correlation coefficient.
adata were analyzed by the Pearson product moment correlation.
bdata were analyzed by the Spearman rank order correlation.
CAT, catalase; CRP, C-reactive protein; GPx, glutathione peroxidase; IL-6,
interleukin-6; SOD, superoxide dismutase; TNF-α, tumor necrosis factor-α.
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and of CAT by 4.5%, but had no effect on that of GPx
[15]. In the present study, coenzyme Q10 supplementa-
tion at 300 mg/d increased the activity of SOD by 48.5%,
CAT by 9.1%, and GPx by 4.3%, and the antioxidant en-
zymes activities were all positively correlated with the level
of coenzyme Q10 after 12 weeks of supplementation
(Table 3). It appears that the 300 mg dose of coenzyme
Q10 has better antioxidation than 150 mg/d.
Both groups of statins-treated CAD patients in this study
had a low level of coenzyme Q10 at baseline (Figure 2),
and the level of coenzyme Q10 was significantly increased
by approximately 5-fold after 4 weeks of coenzyme Q10
supplementation (data not shown; the median level of co-
enzyme Q10 was 0.4 to 2.0 μmol/L), which rapidly adjusted
their low coenzyme Q10 level to normal values (0.5 –
1.7 μmol/L) [29]. In addition, coenzyme Q10 had a syner-
gic effect with vitamin E [30-33]. In this study, we observed
that the level of vitamin E was significantly higher in the
Q10-300 group (Figure 2) and was positively correlated
with the level of coenzyme Q10 after 12 weeks of sup-
plementation (Table 3). Coenzyme Q10 not only pro-
tects vitamin E against superoxide-driven oxidation but
also regenerates vitamin E during antioxidation pro-
cesses [32,33].
CAD is considered to be a chronic inflammation status
[10]. In the present study, the level of TNF-α (Figure 4)
and the changed levels of TNF-α and IL-6 were signifi-
cantly decreased after coenzyme Q10 supplementation
(Table 2). The level of coenzyme Q10 was significantly
negatively correlated with inflammatory markers (TNF-α
and IL-6) (Table 3). Schmelzer et al. [34,35] demonstrated
that coenzyme Q10 could exert anti-inflammation effects
via the reduction of nuclear factor-κB (NF-κB) dependentgene expression. NF-κB can be activated by the reactive
oxygen species and can then up-regulate pro-inflammatory
cytokines expression. However, this NF-κB -activating cas-
cade could be inhibited by antioxidants, such as coenzyme
Q10 [36]. Our previous results [21] showed that coenzyme
Q10 at a dose of 150 mg/d decreased the level of IL-6 by
0.40 pg/mL. In the present study, coenzyme Q10 supple-
mentation at 300 mg/d decreased the levels of TNF-α by
0.30 pg/mL and IL-6 by 0.52 pg/mL. However, coenzyme
Q10 supplementation had no effect on the level of CRP.
As we previously reported, proinflammatory cytokines
(TNF-α and IL-6) reflect the status of inflammatory reac-
tions with more sensitivity (easily changed) than CRP,
which is a product of hepatic stimulation [21]. A higher
level of adiponectin is associated with a lower risk of CAD
[20,37], but coenzyme Q10 supplementation had no effect
on the level of adiponectin in the present study. Nakamura
et al. [20] reported that the concentration of plasma adipo-
nectin was not significantly different between stable angina
pectoris and control subjects. The subjects who had CAD
in this study had not experienced acute myocardial infarc-
tion within the previous 6 months and thus were stable an-
gina pectoris patients, which might be the reason why we
did not find an effect of coenzyme Q10 on adiponectin.
Regarding the safety of statins therapy and its combin-
ation with placebo or coenzyme Q10 in the present study,
there were no clinically significant changes in the subjects’
vital signs, serum chemical values, or hematological values,
and there were no serious adverse events, no complaints
of myalgia or muscle weakness, and no withdrawals due to
adverse events. Thus, coenzyme Q10 at a dose of 300 mg/d
is safe for co-administration with statins therapy.
Two limitations of the present study should be men-
tioned. First, the number of participants was small, al-
though we did recruit more subjects than expected.
Second, a few of the subjects had higher inflammation
in the present study. Only 10% of the subjects had a high
inflammation according to the level of CRP (≥ 3.0 mg/L),
and this finding might have contributed to observing the
null effect on CRP after the supplementation. Large stu-
dies are needed to establish the beneficial effect of co-
enzyme Q10 supplementation on inflammation, especially
in subjects who have high inflammation status.Conclusions
In conclusion, we have demonstrated that coenzyme
Q10 supplementation at a dose of 300 mg/d significantly
increased antioxidant enzymes activities and reduced the
levels of inflammatory markers (TNF-α and IL-6) in CAD
patients during statins therapy. CAD patients might bene-
fit from using coenzyme Q10 supplements to increase
their antioxidation and anti-inflammation capacity during
statins therapy.
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